文献速递眼底病与葡萄膜炎青光眼

68岁及以上Medicare按服务收费受益人中主要眼病诊断患病率与发病率趋势

Trends in the Diagnosed Prevalence and Incidence of Major Eye Diseases in Medicare Part B Fee-for-Service Beneficiaries 68 Years of Age or Older.
PubMed 文献 · Ophthalmology · 2023-07-24

该研究分析2005至2020年Medicare按服务收费(FFS)受益人的行政理赔数据,计算年龄相关性黄斑变性(AMD)、糖尿病视网膜病变(DR)(糖尿病患者中)和青光眼的年度诊断患病率与发病率。结果显示2005至2019年任何研究疾病的诊断患病率从16.4%升至17.9%,诊断发病率从4.9%降至4.2%;AMD诊断患病率从6.8%升至9.4%,糖尿病患者中任何DR诊断患病率从9.3%降至9.0%但威胁视力DR从2.0%升至3.4%,青光眼诊断患病率从8.8%降至8.1%;2020年所有诊断的患病率和发病率均下降。

要点

  • 2005至2019年任何研究疾病的诊断患病率从16.4%(n=3 628 996)升至17.9%(n=3 731 281)。
  • 同期诊断发病率从4.9%(n=954 878)降至4.2%(n=757 696)。
  • AMD诊断患病率从6.8%(n=1 504 770)升至9.4%(n=1 965 176);糖尿病患者中任何DR从9.3%(n=504 135)降至9.0%(n=532 859),威胁视力DR从2.0%升至3.4%;青光眼从8.8%(n=1 951 141)降至8.1%(n=1 692 837)。

核心结论

  • 与较早的流行病学估计相比,近年所研究每种疾病的诊断患病率更高。
  • 这些发现可能为公共卫生和政策规划及资源分配提供信息,以应对日益老龄化的美国人群的眼健康。

研究设计与样本

  • 研究设计为Medicare行政理赔数据分析。
  • 研究对象为2005至2020年连续参加Part A和Part B 3年(包括指数年和2年回看期)的68岁及以上Medicare FFS受益人。
  • 计算年度横断面诊断患病率和发病率,并使用直接标准化法进行年龄标准化,还计算了按人口学特征(年龄、性别、种族和族裔)分层的率。

主要发现

  • 2005年基线时,60%的纳入受益人为女性,20%为85岁及以上,86%为非西班牙裔白人,四分之一有糖尿病诊断。
  • 2005至2019年,任何研究疾病的诊断患病率从16.4%(n=3 628 996)升至17.9%(n=3 731 281)。
  • 诊断发病率从2005年4.9%(n=954 878)降至2019年4.2%(n=757 696)。
  • AMD诊断患病率从6.8%(n=1 504 770)升至9.4%(n=1 965 176);糖尿病患者中任何DR诊断患病率从9.3%(n=504 135)降至9.0%(n=532 859),但威胁视力DR诊断患病率从2.0%升至3.4%;任何诊断青光眼患病率从8.8%(n=1 951 141)降至8.1%(n=1 692 837)。
  • 2020年所有诊断的患病率和发病率均下降;研究期间检测到每种疾病诊断患病率和发病率的人口学差异。

关键数值与推荐

  • 研究未制定或引用诊断标准或推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study contemporary trends in the diagnosed prevalence and incidence of age-related eye diseases among Medicare Fee-for-Service (FFS) beneficiaries. DESIGN: Analysis of Medicare administrative claims data. PARTICIPANTS: Medicare FFS beneficiaries 68 years of age and older from 2005 through 2020 who were enrolled continuously in both Part A and Part B for 3 years, including the index year and a 2-year lookback period. METHODS: Annual cross-sectional diagnosed prevalence and incidence rates were calculated. Age standardization was performed using the direct standardization method to account for changes in the age structure of the study population. Rates stratified by demographics (age, sex, race, and ethnicity) also were calculated. MAIN OUTCOME MEASURES: Annual prevalence and incidence of diagnosed age-related macular degeneration (AMD), diabetic retinopathy (DR) (among those with diabetes), and glaucoma. RESULTS: At baseline, in 2005, 60% of included beneficiaries were female, 20% were 85 years of age or older, 86% were non-Hispanic White, and one-quarter had a diagnosis of diabetes. From 2005 through 2019, the prevalence of a diagnosis of any of the conditions studied increased from 16.4% (n = 3 628 996) to 17.9% (n = 3 731 281). Diagnosed incidence decreased over this period from 4.9% (n = 954 878) in 2005 to 4.2% in 2019 (n = 757 696). The diagnosed prevalence of AMD increased from 6.8% (n = 1 504 770) to 9.4% (n = 1 965 176); the diagnosed prevalence of any DR among those with diabetes decreased from 9.3% (n = 504 135) to 9.0% (n = 532 859), although the diagnosed prevalence of vision-threatening DR increased from 2.0% to 3.4%; and the diagnosed prevalence of any diagnosed glaucoma decreased from 8.8% (n = 1 951 141) to 8.1% (n = 1 692 837). In 2020, the diagnosed prevalence and incidence of all diagnoses decreased. During the study period, we detected demographic differences in the prevalence and incidence of diagnosis of each condition. CONCLUSIONS: This study presents updated data on the prevalence and incidence of diagnosed major chronic, age-related eye diseases among Medicare FFS beneficiaries. Compared with older epidemiologic estimates, we found that the diagnosed prevalence of each condition studied was higher in more recent years. These findings may inform public health and policy planning and resource allocation to address the eye health of an increasingly older United States population. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Ehrlich JR, Andes LJ, Eisenberg A, et al. Trends in the Diagnosed Prevalence and Incidence of Major Eye Diseases in Medicare Part B Fee-for-Service Beneficiaries 68 Years of Age or Older. Ophthalmology. 2023. PMID: 37495083. doi:10.1016/j.ophtha.2023.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。